Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: Dealing with obstacles hindering progress

Cancer Discovery

Volumn 1, Issue 3, 2011, Pages 207-212

  Garcia, Victor Moreno ^a   Cassier, Philippe A ^b   de Bono, Johann ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FIGITUMUMAB; IMATINIB; INIPARIB; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VELIPARIB; VEMURAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CERTIFICATION; CIRCULATING TUMOR CELL; DNA SEQUENCE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; GOOD LABORATORY PRACTICE; HUMAN; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; HUMANS; NEOPLASMS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84858268074     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0161     Document Type: Article

References (5)

1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25: 420-8.
2. Basu B, Olmos D, de Bono JS. Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 2011;104:1-3.
3. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10:514-23.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Fu P, Dowlati A, Schluchter M. Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. J Clin Oncol 2009;27:4135-41.